Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK

Journal of Medical Economics

Volumn 20, Issue 8, 2017, Pages 840-849

  Prabhu, Vimalanand ^a   Foo, Jason ^b   Ahir, Harblas ^c   Sarpong, Eric ^a   Merchant, Sanjay ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MAPI GROUP   (Netherlands)

^c Merck Sharp & Dohme Limited   (United Kingdom)

Author keywords

antimicrobial resistance; ceftolozane; Cost effectiveness; economic; empiric therapy; modeling; QALY

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ABDOMINAL INFECTION; ADD ON THERAPY; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; DRUG COST; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HOSPITALIZATION COST; HUMAN; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; NONHUMAN; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; QUALITY ADJUSTED LIFE YEAR; TREATMENT INDICATION; UNITED KINGDOM; VERY ELDERLY; ANALOGS AND DERIVATIVES; CLINICAL PROTOCOL; COMBINATION DRUG THERAPY; DRUG COMBINATION; ECONOMICS; GRAM NEGATIVE INFECTION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STATISTICAL MODEL;

ANTI-BACTERIAL AGENTS; BACTERIOLOGICAL TECHNIQUES; CEPHALOSPORINS; CLINICAL PROTOCOLS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; METRONIDAZOLE; MODELS, ECONOMETRIC; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN; QUALITY-ADJUSTED LIFE YEARS; UNITED KINGDOM;

EID: 85020461086     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.1080/13696998.2017.1333960     Document Type: Article

References (31)

1. Menichetti F, Sganga G., Definition and classification of intra-abdominal infections. J Chemo 2009;21(Suppl1):3–4
2. Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections in Europe:a comprehensive review of the CIAO study. W J Emerg Surg 2012;7:36
3. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children:guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect 2010;11:79–109
4. Davey PG, Marwick C., Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect Offic Publ Eur Soc Clin Microbiol Infect Dis 2008;14(Suppl3):15–21
5. Falagas ME, Barefoot L, Griffith J, et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996;15:913–21
6. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections:a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–74
7. Edelsberg J, Berger A, Schell S, et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect 2008;9:335–47
8. Dalfino L, Bruno F, Colizza S, et al. Cost of care and antibiotic prescribing attitudes for community-acquired complicated intra-abdominal infections in Italy:a retrospective study. W J Emerg Surg 2014;9:39
9. Public Health England. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) 2010 to 2014. Report 2015. 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/477962/ESPAUR_Report_2015.pdf 9 September 2016
10. British Society for Antimicrobial Chemotherapy. BSAC Resistance Surveillance Project. 2015. http://www.bsacsurv.org/. [Last accessed 5 May 2017]
11. Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections worldwide:the definitive data of the CIAOW Study. W J Emerg Surg 2014;9:37
12. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2011. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net); Stockholm:ECDC 2012
13. Eckmann C, Dryden M, Montravers P, et al. Antimicrobial treatment of “complicated” intra-abdominal infections and the new IDSA guidelines? A commentary and an alternative European approach according to clinical definitions. Eur J Med Res 2011;16:115–26
14. Zerbaxa U.S. Prescribing Information. 2016. http://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf. [Last accessed 8 December 2015]
15. ® (Piperacillin and Tazobactam for Injection, USP) Prescribing Information. 2017. http://labeling.pfizer.com/showlabeling.aspx?id = 416. [Last accessed 5 May 2017]
16. Office for National Statistics. A1.1 2014-based expectation of life, 1981–2064, principal projection, United Kingdom; 2015. http://www.ons.gov.uk/ons/rel/lifetables/past-and-projected-data-from-the-period-and-cohort-life-tables/2014-based/rft-a1-1.xls 18 February 2016
17. Sturkenboom MC, Goettsch WG, Picelli G, et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005;60:438–43
18. Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004;23:682–7
19. Department of Health. NHS reference costs 2013 to 2014. 2015. https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014 18 February 2016
20. Monthly Index of Medical Specialties. 2016. http://www.mims.co.uk/ 18 February 2016
21. Jansen JP, Kumar R, Carmeli Y., Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health J Int Soc Pharmacoecon Outcomes Res 2009;12:234–44
22. Scottish Medicines Consortium. Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). October 2014. https://www.scottishmedicines.org.uk/files/submissionprocess/Guidance_on_NPAF_Final_October_2014.doc 18 February 2016
23. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. https://www.nice.org.uk/article/pmg9/chapter/foreword 18 February 2016
24. Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling:a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health J Int Soc Pharmacoecon Outcomes Res 2012;15:812–20
25. Marchaim D, Gottesman T, Schwartz O, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemo 2010;54:5099–104
26. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa:risk factors and clinical impact. Antimicrob Agents Chemo 2006;50:43–8
27. National Institute for Health and Care Excellence. Judging whether pubilc health interventions offer value for money. Local government briefing [LGB10]. 2013. https://www.nice.org.uk/advice/lgb10/chapter/judging-the-cost-effectiveness-of-public-health-activities#nices-approach-to-assessing-public-health-interventions 5 May 2017
28. Zilberberg MD, Mody SH, Chen J, et al. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia. Surg Infect 2010;11:409–17
29. Kauf TL, Medic G, Dryden M, et al. Use of surveillance data to examine the cost-effectiveness of alternative approaches to empiric antibiotic therapy in gram-negative nosocomial pneumonia. Am J Respir Crit Care Med 2015;191:A5443
30. Prabhu V, Sen S, Miller B, et al. Using an economic model to choose initial appropriate antibiotic therapy based on differences in in-vitro susceptibility to cftolozane/tazobactam and piperacillin/tazobactam. Value Health J Int Soc Pharmacoecon Outcomes Res 2015;18:A536
31. Kauf TL, Prabhu VS, Medic G, et al. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. BMC Infect Dis 2017;17:314